belantamab mafodotin

💊Medication

Generic name

Belantamab Mafodotin

Brand names

Blenrep

Active ingredients

belantamab

Route

Intravenous

Type

Human Prescription Drug

Manufacturer

GlaxoSmithKline LLC

Indications: 1 INDICATIONS AND USAGE BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLE… (per FDA label)

• PHASE1/PHASE2RECRUITING
  Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaUniversitätsklinikum Hamburg-Eppendorf · NCT05853965
• PHASE1/PHASE2ACTIVE_NOT_RECRUITING
  Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomidePETHEMA Foundation · NCT05060627
• PHASE2RECRUITING
  Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaM.D. Anderson Cancer Center · NCT05091372
• PHASE1/PHASE2RECRUITING
  A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsGlaxoSmithKline · NCT05714839
• PHASE1/PHASE2TERMINATED
  Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple MyelomaUniversity of Maryland, Baltimore · NCT04896658
• PHASE1/PHASE2ACTIVE_NOT_RECRUITING
  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMGlaxoSmithKline · NCT07150091

via ClinicalTrials.gov